Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

Mast cell tumor (MCT) is the most common cutaneous neoplasm in dogs and wide surgical resection is the current first-line treatment. However, recurrence is common and often requires more specialist and expensive therapies. Tigilanol tiglate is a novel small molecule drug delivered by intratumoral in...

Full description

Bibliographic Details
Main Authors: Jane Miller, Justine Campbell, Andrew Blum, Paul Reddell, Victoria Gordon, Peter Schmidt, Stewart Lowden
Format: Article
Language:English
Published: Frontiers Media S.A. 2019-04-01
Series:Frontiers in Veterinary Science
Subjects:
Tigilanol tiglate
EBC-46
mast cell tumor
protein kinase C
solid tumors
intratumoral injection
Online Access:https://www.frontiersin.org/article/10.3389/fvets.2019.00106/full

Internet

https://www.frontiersin.org/article/10.3389/fvets.2019.00106/full

Similar Items